In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

“ Psoriasis is an inflammatory skin disorder, due to an overactive immune system,” said Dr. Omar Noor. “That over active immune system produces inflammation in the skin that causes the skin to develop ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Can-Fite BioPharma initiates pivotal Phase 3 study for psoriasis treatment using oral drug Piclidenoson, targeting moderate to severe cases. Can-Fite BioPharma Ltd. announced the initiation of a ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

The Company’s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite’s liver drug, Namodenoson ...

"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, together with its progressive effectiveness over time, make it an ideal drug ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.